Breast Imaging

Why Is Follow-Up Ultrasound Best for a Probably Benign Breast Mass in Pregnancy?

·
Why Is Follow-Up Ultrasound Best for a Probably Benign Breast Mass in Pregnancy?

A 32-year-old patient, 24 weeks pregnant with her first child, presents for a follow-up visit. She noticed a new, palpable, rubbery lump in her right breast a few weeks ago. An initial targeted breast ultrasound was performed, and the report describes a well-circumscribed oval mass, wider than it is tall, with findings consistent with a BI-RADS 3, or “probably benign,” category. The patient is anxious, and you are considering the next step. Is immediate biopsy necessary? Should you order a mammogram just to be safe? Or is surveillance the correct path? This is a common and delicate clinical decision, balancing diagnostic certainty with maternal and fetal safety.

This article provides a detailed workflow for this specific scenario, guided by the American College of Radiology (ACR) Appropriateness Criteria. For a pregnant patient with a palpable mass and probably benign initial ultrasound findings, the next recommended imaging study is a follow-up US breast, which the ACR rates as Usually appropriate.

Who Fits This Clinical Scenario?

This guidance is specifically for a pregnant female who has a palpable breast mass where an initial diagnostic ultrasound has already been performed and the findings were categorized as probably benign (BI-RADS 3). The key element is that this is the next step in management, not the initial workup. The patient has a known, characterized finding that has a very high likelihood of being benign, but for which stability has not yet been documented.

This workflow does not apply to several similar-sounding but distinct clinical situations:

  • Initial Imaging for a New Mass: If your pregnant patient presents with a new palpable mass and has not yet had any imaging, the workup starts with an initial diagnostic ultrasound. That falls under a different ACR variant. This article addresses the management after that initial ultrasound is complete and shows a probably benign finding.
  • Suspicious Ultrasound Findings: If the initial ultrasound revealed suspicious features (e.g., irregular shape, spiculated margins, posterior acoustic shadowing) resulting in a BI-RADS 4 or 5 assessment, the next step is not further imaging but a referral for image-guided biopsy.
  • Screening Mammography: This guidance is for a diagnostic workup of a palpable finding, not for routine breast cancer screening in an asymptomatic pregnant patient.

Correctly identifying your patient’s place in the diagnostic pathway is crucial for avoiding unnecessary procedures or delays in care.

What Diagnoses Are You Working Up in This Scenario?

When managing a probably benign palpable mass in a pregnant patient, the differential diagnosis is heavily weighted toward benign and physiologic causes, though the small possibility of malignancy must always be considered. The goal of short-term follow-up imaging is to confirm stability and confidently rule out a slow-growing cancer.

Lactational Adenoma or Tubular Adenoma: These are benign epithelial tumors that are hormonally sensitive and often arise or grow during pregnancy and lactation. On ultrasound, they typically appear as well-circumscribed, hypoechoic masses and are a very common cause of new palpable lumps in this population.

Fibroadenoma: The most common benign breast tumor in young women, a fibroadenoma can be stimulated by the hormonal changes of pregnancy, causing it to enlarge and become palpable for the first time. Like lactational adenomas, they usually appear well-circumscribed on ultrasound.

Galactocele: This is a milk-filled cyst caused by a blocked duct. While more common during lactation, they can also occur in late pregnancy. Their appearance on ultrasound can vary from a simple cyst to a complex cystic and solid mass, but they often have features that suggest a benign etiology.

Pregnancy-Associated Breast Cancer (PABC): Although uncommon, breast cancer can be diagnosed during pregnancy. Some cancers can present as well-circumscribed masses, mimicking a benign fibroadenoma. The primary purpose of follow-up imaging for a BI-RADS 3 lesion is to ensure it is not one of these rare, well-differentiated malignancies by demonstrating its stability over a short interval.

Why Is a Follow-Up US breast the Recommended Study for This Presentation?

For a pregnant patient with a palpable mass and initial ultrasound findings categorized as probably benign, the ACR designates a short-term follow-up US breast as Usually appropriate. This recommendation is rooted in maximizing diagnostic information while minimizing any potential risk to the mother and fetus.

The rationale is straightforward: a BI-RADS 3 finding has a less than 2% chance of being malignant. The standard of care is to demonstrate stability with short-term follow-up rather than proceeding directly to an invasive procedure. Ultrasound is the ideal modality for this surveillance. It uses no ionizing radiation (0 mSv) and provides excellent high-resolution detail of breast parenchyma, which is often dense and difficult to evaluate with other methods during pregnancy. It can precisely measure the lesion and assess for any change in size or morphology, such as the development of irregular borders or internal vascularity, which would be red flags for malignancy.

Alternative imaging studies are rated lower for clear reasons in this specific context:

  • Mammography diagnostic: Rated Usually not appropriate. The physiologic and hormonal changes of pregnancy cause increased breast density, which significantly lowers the sensitivity of mammography. Furthermore, while the fetal radiation dose from a properly shielded mammogram is very low (☢☢ 0.1-1mSv), the principle of ALARA (As Low As Reasonably Achievable) dictates avoiding any ionizing radiation when a non-radiation alternative like ultrasound is superior for the clinical question at hand.
  • MRI breast without and with IV contrast: Rated Usually not appropriate. Standard breast MRI protocols require the use of a gadolinium-based contrast agent. While data is limited, there is a theoretical risk associated with gadolinium crossing the placenta and its effects on the fetus are not fully known. Therefore, its use is generally avoided during pregnancy unless the potential benefit clearly outweighs the potential risk, which is not the case for following up a probably benign finding.
  • Image-guided core biopsy breast: Rated Usually not appropriate. For a finding with a >98% chance of being benign, subjecting the patient to an invasive procedure is not the recommended first step. Biopsy is reserved for lesions that are suspicious at initial presentation or that demonstrate concerning changes on follow-up imaging.

What’s Next After the Follow-Up US breast? Downstream Workflow

The results of the short-term follow-up ultrasound will dictate the next steps in management. The typical interval for this first follow-up is 3 to 6 months, though this may be adjusted based on the specific findings and degree of clinical concern.

If the Finding is Stable or Decreased in Size: This is the most common and reassuring outcome. Stability on a 6-month follow-up ultrasound confirms the benign nature of the lesion. The finding can be downgraded to BI-RADS 2 (Benign), and the patient can be advised to return to routine postpartum care. No further short-term imaging is necessary for this specific lesion.

If the Finding Has Grown or Developed Suspicious Features: Any significant interval growth or change in morphology (e.g., loss of circumscribed margins, development of posterior shadowing) is a red flag. The lesion should be upgraded to a suspicious category (BI-RADS 4 or 5). The next step is no longer imaging but rather an ultrasound-guided core needle biopsy to obtain a definitive pathologic diagnosis. This shift in management underscores the importance of follow-up; it acts as a crucial safety net to catch the rare malignancy that may mimic a benign lesion.

If the Finding Has Resolved: Some physiologic changes, like small galactoceles, may resolve on their own. If the follow-up ultrasound shows complete resolution of the palpable finding, the workup is complete, and the patient can be reassured.

Pitfalls to Avoid (and When to Get Help)

Navigating this scenario requires careful communication and adherence to established guidelines. Here are a few common pitfalls to avoid:

  • Prematurely Reassuring the Patient: While a BI-RADS 3 finding is highly likely to be benign, it is not definitively so. It is critical to communicate the importance of completing the recommended short-term imaging follow-up to confirm stability.
  • Losing the Patient to Follow-Up: Pregnancy and the postpartum period are busy and overwhelming times. Ensure the patient understands the follow-up plan and has a scheduled appointment before leaving the office. A missed follow-up is a significant patient safety risk.
  • Ignoring Clinical Changes: The imaging plan is based on the findings at one point in time. Instruct the patient to return immediately if she notices any rapid growth of the mass, skin changes (dimpling, redness), or nipple retraction, as these are clinical red flags that warrant immediate re-evaluation, regardless of the scheduled follow-up date.

If the clinical or imaging picture becomes confusing or concerning, do not hesitate to escalate. A discussion with the interpreting breast radiologist or a referral to a breast surgeon can provide valuable guidance and ensure the patient receives appropriate and timely care.

Related ACR Topics and Tools

For a comprehensive overview of all clinical variants related to breast imaging during pregnancy, please consult our parent guide. For other tools to help with imaging decisions, see the resources below.

Frequently Asked Questions

What exactly does a ‘probably benign’ or BI-RADS 3 finding mean in a pregnant patient?

A BI-RADS 3 category signifies a finding that has a very high probability (greater than 98%) of being benign. However, it is not definitively benign based on its appearance alone. In a pregnant patient, this often represents a hormonally stimulated benign lesion like a fibroadenoma or a lactational adenoma. The standard of care is short-term imaging follow-up to establish its stability, which provides the final confirmation of its benign nature.

How long is ‘short-term follow-up’ for a breast mass in pregnancy?

The standard recommendation for a BI-RADS 3 lesion is an initial follow-up at 6 months, followed by additional scans at 12 and 24 months to ensure long-term stability. However, in the context of pregnancy, the radiologist may recommend a shorter initial interval, such as 3-6 months, to ensure stability during a period of rapid hormonal change. The follow-up plan should be clearly stated in the radiology report.

Is mammography ever appropriate for a palpable mass during pregnancy?

While ultrasound is the primary imaging tool, mammography may be considered in specific situations, such as when ultrasound findings are highly suspicious for malignancy. In such cases, the information gained from mammography (e.g., detecting suspicious microcalcifications) may outweigh the very small radiation risk. However, for a probably benign finding, it is rated ‘Usually not appropriate’ due to its lower sensitivity in dense breast tissue and the availability of a non-radiation alternative.

Why is MRI with contrast ‘Usually not appropriate’ in this situation?

Breast MRI relies on gadolinium-based contrast agents to detect and characterize lesions. There is evidence that gadolinium can cross the placenta and enter the fetal circulation. While no definitive harm has been proven in humans, its long-term effects on the fetus are unknown. Therefore, its use is avoided during pregnancy unless absolutely essential for a life-threatening diagnosis, a threshold that is not met by the follow-up of a probably benign lesion.

If the follow-up ultrasound shows the mass has grown, what is the immediate next step?

If a probably benign mass demonstrates significant growth or develops suspicious features on a follow-up ultrasound, it is upgraded to a suspicious category (BI-RADS 4 or 5). The immediate next step is an ultrasound-guided core needle biopsy to obtain a tissue diagnosis. Further imaging is not warranted; the priority becomes definitive pathologic characterization.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026